Commentary

Prospects of malaria vaccination in Nigeria: Anticipated challenges and lessons from previous vaccination campaigns

ARTICLE INFO

Keywords
Malaria
Vaccine
Disease
Plasmodium falciparum
Nigeria

ABSTRACT

Malaria is a severe public health issue in Nigeria, with higher morbidity and mortality rates than any other country. An estimated 100 million malaria cases and over 300,000 deaths are recorded yearly in Nigeria. Vaccination is an effective strategy in combating and eliminating infectious diseases such as malaria, thus, the deployment of a prospective malaria vaccine in Nigeria offers hope to the country’s health sector. However, vaccination programmes face challenges, particularly in communities that are difficult to reach geographically or culturally, and these obstacles can only be overcome through continued international, national, and individual commitment. There is a need for expanded and continuous public health information, education, and communication particularly on contemporary health issues such as malaria and vaccination hesitancy. This will enable easier implementation and compliance to strategies for the sustainable control and eventual elimination of malaria. This article highlights some of the lessons learned from previous vaccination programs in Nigeria and how the insight gotten can be pivotal in ensuring the success of a prospective malaria vaccination programme in Nigeria.

1. Introduction

The prospect of a world free of malaria has fueled significant development, and the remarkable drop in malaria mortality between 2000 and 2015 can be described as a victory of modern public health, as the global number of malaria cases has fallen by 22% and malaria-related deaths have decreased by 50% (Shretta et al., 2018) [1]. However, malaria still causes over one million deaths each year, largely in Africa, with more than 250,000 children dying yearly from the disease in Sub-Saharan Africa (Adoju, 2019) [2]. Despite the use of drugs, insecticide-treated nets, and other interventions to reduce the impact of the disease, malaria remains a formidable foe (Otarigho, 2012) [3]. The distribution of an effective and affordable malaria vaccine would help curb the adverse health and socioeconomic effects of the disease.

1.1. Burden and endemicity of malaria in Nigeria

Nigeria has the highest malaria burden worldwide, with an estimated 100 million cases every year and over 300,000 deaths, and together with the Republic of Congo, accounts for 36% of all worldwide malaria cases (Thornton, 2020) [4]. Nigeria recorded the largest number of malaria cases (25% of global malaria cases) and the highest number of deaths (24% of global malaria deaths) in 2018, according to the 2019 World Malaria Report (Thornton, 2020) [4]. Malaria is endemic in Nigeria due to the climatic and environmental conditions that favour mosquito breeding, such as stagnant water bodies, land pollution, and poor sewage disposal. This leaves most Nigerians vulnerable to malaria, as a large proportion of the population live in rural areas. The most vulnerable groups are children, pregnant women and non-immune individuals, as malaria is responsible for 11% and 30% of maternal and infant mortality, respectively (Thornton, 2020) [4]. Malaria is also a leading cause of miscarriage, low birth weight, maternal anemia, and maternal death (Kidanto et al., 2009) [5]. Aside the morbidity and mortality [26, 27], the high costs of malaria treatment and eradication activities have created a major economic burden for the Nigerian health sector. The availability of a cost-effective and accessible malaria vaccine in Nigeria will strengthen malaria eradication efforts and public health quality.

1.2. Status of P. falciparum malaria vaccine candidates

The development of a malaria vaccine is an active area in vaccine research and development but is accompanied by challenges associated with the complex life cycle, morphological changes, and varying antigenic sites of the malaria parasite Plasmodium falciparum (Arama & Torey-Bloemberg, 2014) [6]. The malaria vaccine candidates target specific stages of the parasite’s life cycle, and mainly include the transmission-blocking vaccines (TBVs), the pre-erythrocytic vaccines (PEVs), and the blood-stage vaccines (BSVs). Details of the various malaria vaccine candidates and their clinical trial status are outlined in Table 1.

1.3. Progress of malaria vaccination trials in African countries

Data from malaria vaccine trials so far show good levels of efficacy in immunogenicity and protection of the trial subjects, mostly children with severe malaria or high vulnerability to the disease. Malaria vaccine trials have been successfully implemented in 7 African countries, including Kenya, Burkina Faso, Malawi, Ghana and Mali, amongst others. The earlier approved RTS,S malaria vaccine has undergone completion of phase III clinical trials, with recorded efficacies of 55% within 12 months and a cumulative 39% over a period of four years (Nakkazi, 2021) [8]. Also, phase III clinical trials have commenced for
Annals of Medicine and Surgery 81 (2022) 104385

Table 1
P. falciparum malaria vaccine candidates undergoing clinical trials in African subpopulations (National Library of Medicine, n.d.) [7].

| Vaccine candidate | Vaccine category | Immuno type | Current status |
|------------------|-----------------|-------------|----------------|
| RTS,S            | PEV             | Subunit     | Phase 4        |
| R21              | PEV             | Subunit     | Phase 1/2      |
| Full-length CSP  | PEV             | Subunit     | Phase 1        |
| PFSF Vaccine     | PEV, WSV        | Whole sporozoite (radiation attenuation) | Phase 2 |
| Chemoprophylaxis Vaccination (CVac) | PEV, WSV | Whole sporozoite (chemical attenuation) | Phase 2 |
| Genetically attenuated parasite (GAP) vaccines | PEV, WSV | Whole sporozoite (genetic attenuation) | Phase 1 |
| PR1H5            | BSV             | Subunit     | Phase 1        |
| AMA1–RON2        | BSV             | Subunit     | Preclinical     |
| PSEA-1           | BSV             | Subunit     | Preclinical     |
| PI-GARP          | BSV             | Subunit     | Preclinical     |
| Chemically attenuated parasite (CAP) vaccines | BSV | Whole blood-stage | Phase 1 |
| VAR2CSA (Placental malaria) | BSV, PMV | Subunit | Phase 1 |
| Pf25             | TBV             | Subunit     | Phase 1        |
| Pf230            | TBV             | Subunit     | Phase 2        |
| Pf48/45          | TBV             | Subunit     | Preclinical     |

PEV – Pre-erythrocytic vaccine; WSV – Whole sporozoite vaccine; BSV – Blood stage vaccine; PMV – Placental malaria vaccine; TBV – Transmission-blocking vaccine

1.4. Anticipatory challenges of a malaria vaccine and lessons from previous vaccination campaigns in Nigeria

1.4.1. The need to address misinformation and vaccine hesitancy

In African countries like Nigeria, vaccination has always been impeded by vaccine hesitancy due to the fear of adverse vaccine effects (Adesia et al., 2021) [13]. For example, during the onset of the COVID-19 vaccination programme in Nigeria, certain negative propagandas surfaced, such as the belief that the vaccines were administered with an ulterior motive to render males sterile, implant tracking microchips, or even cause death in vaccine recipients in Africa (Asishana, 2021; Schönbauer, 2022) [14,15]. Similar vaccine misconceptions occurred in the past during the introduction of the polio vaccination programme in Northern Nigeria (Renne, 2014) [16], and could likely emerge during a prospective malaria vaccination campaign. These challenges were resolved through collaborations between the vaccination staff and rural community leaders, including traditional and religious authorities (Effiong et al., 2021; Elebesunu & Ubani, 2021) [17, 18]. Thus, a successful malaria vaccination programme in Nigeria requires sufficient involvement of community stakeholders to enhance vaccine acceptance among the community indigenes. Also, a comprehensive information surveillance programme should be implemented at all levels of the Nigerian government to identify and correct any misinformation concerning the prospective malaria vaccine.

1.4.2. Lesson 2: The need to address vaccine storage and transportation challenges

For the storage and distribution of the RTS,S malaria vaccine to take place, an effective cold chain system at defined temperatures is necessary (Asante et al., 2016) [19]. Currently, the malaria vaccine is stored at 2–8 ºC, while other malaria vaccine candidates in development are stored and transported at even lower temperatures [19]. Insufficient cold chain infrastructure, coupled with power supply interruptions, are probable challenges to vaccine storage and distribution in Nigeria, as poor storage may compromise the quality of the vaccine. For instance, during the polio vaccination campaigns, poor storage and transportation systems led to the expiration of some of the polio vaccines, and according to reports, those who received such vaccines remained susceptible to the virus (Arita & Nakane, 2008) [20]. In this regard, it is important for the Nigerian government and health policy makers to channel resources into the establishment of quality cold chain equipment for the storage and transportation of vaccines.

1.4.3. Lesson 3: The need to include larger population subgroups in clinical trials

Vaccine efficacy and safety are often measured through randomized clinical trials (RCTs), which have a limitation of never being conducted in all the subpopulations where the vaccine will eventually be administered (Poland et al., 2009) [21]. This may not reflect a complete real-world scenario, as it is possible that vital subpopulations might be overlooked. Most clinical trials for the RTS,S malaria vaccine are targeted at infants and young children (RTS, 2014) [22], and as a result, there is a dearth of information on the efficacy and safety of these vaccines among older populations. Understandably, the younger population is at higher risk of mortality from malaria, but a malaria-endemic country like Nigeria would not be favoured if the efficacy of these vaccines is not tested in older subpopulations. Also, most final stage clinical trials (phase III) only assess the efficacy and safety of vaccines in a well-defined population, limiting the participants to a narrow age range. For instance, pregnant women, infants, and young adolescents were not included in various clinical trials for the COVID-19 vaccines (Principi & Esposito, 2021) [23]. The results generated from such trials might not be completely suitable for generalizing the data to a larger population, and for special cases. Also, the geriatric population has often been excluded from most clinical trials, and as a result, reports have shown lower responsiveness of elderly individuals to vaccines such as the Hepatitis B vaccine, Herpes Zoster vaccine, Influenza vaccine, and even the COVID-19 vaccine (Cherubini et al., 2010; Veronese et al., 2021) [24,25,28]. This paucity of data among certain demographic populations may limit vaccine coverage and possibly encourage vaccine hesitancy. There is a need for the malaria vaccine clinical trials to extend to other subpopulations for equal demographic representation and improved chances of herd immunity.

2. Conclusion

The deployment of the malaria vaccine offers great promise, as seen in the African countries fielding the clinical trials, however, certain hurdles must be overcome to ensure the reality of an effective vaccination programme in Nigeria. Synergised efforts at the national and subnational levels are necessary to address these challenges, with a view to enabling easier implementation of a malaria vaccination programme in Nigeria. This will ensure significant progress towards the successful control and elimination of malaria in Nigeria, and in Africa as a whole.

Ethical approval

Not Applicable.
Sources of funding
None.

Author contribution
Elebbeunu E.E, Uwishema O

Annals of medicine and surgery

Guarantor
Emmanuel Ebuka Elebesunu.

Acknowledgement

Declaration of competing interest
No conflicts of interest declared.

Consent
Not Applicable.

Data availability statement
Not applicable.

References
[1] R. Shretta, J. Liu, C. Cotter, J. Cohen, C. Dolenz, K. Makomva, G. Newby, D. Némark, A. Phillips, A. Tatarsky, R. Gosling, R. Feachem, Malaria elimination and eradication, in: K.R. Holmes, S. Bertozi, R.R. Bloom, P. Jha (Eds.), Major Infectious Diseases, third ed., The International Bank for Reconstruction and Development/The World Bank, Washington (DC), 2017 Nov 3 https://doi.org/10.1596/978-1-4648-0524-0-ch12 (Chapter 12).
[2] P. Adepoju, RTS,S malaria vaccine pilots in three African countries, Lancet 393 (10182) (2019 Apr 27) 1685, https://doi.org/10.1016/S0140-6736(19)30937-7.
[3] B. Otariogho, Malaria vaccine: hope in the future, Nat. Sci. 10 (11) (2012) 87–95.
[4] J. Thornton, Covid-19: keep essential malaria services going during pandemic, urges WHO, BMJ 369 (2020 Apr 23), https://doi.org/10.1136/bmj.m1637.
[5] H.L. Kidanto, I. Mogren, G. Lindmark, S. Massawe, L. Nystrom, Risks of undermined delivery and low birth weight are increasingly independent by severity of maternal anaemia, S. Afr. Med. J. 99 (2) (2009 Feb) 98–102.
[6] C. Arama, M. Troye-Blomberg, The path of malaria vaccine development challenges and perspectives, J. Intern. Med. 275 (5) (2014 May) 456–466, https://doi.org/10.1111/j.1469-7372.2013.02939.x.
[7] National Library of Medicine (n.d.). Database of clinical trials. Clin. Trials. Gov., Available at: https://clinicaltrials.gov/ct2/results?term=RTS,S.&rank=2
[8] E. Nakkazi, A made-in-Africa malaria vaccine: efforts in research has led to vaccine candidates, Nat. News. (2021). Available at: https://www.nature.com/articles/articles_v14418-021-00051-y. (Accessed 5 July 2022).
[9] A. Hill, A global team of researchers has developed a malaria vaccine with “unprecedented” effectiveness, Quarta Africa (2021). Available at: https://qs.africa/200108/new-malaria-vaccine-has-landmark-results-in-burkinsa-faso-trial/, (Accessed 5 July 2022).
[10] World Health Organization, Over 1 million African children protected by first malaria vaccine, Available at: https://www.who.int/news/item/21-04-2022-over-1-million-african-children-protected-by-first-malaria-vaccine, 2022. (Accessed 5 July 2022).
[11] B.M. Kuehn, Vaccine development is charting a new path in malaria control, JAMA 327 (6) (2022 Feb 8) 510–512, https://doi.org/10.1001/jama.2022.0627.
[12] E. Patussiuillard, J. Griffin, S. Bhattacharya, A. Ghan, C. Dubuk, Global investment targets for malaria control and elimination between 2016 and 2030, BMJ Glob Health 2 (2) (2017 May 16), e000176, https://doi.org/10.1136/bmjgh-2016-000176.
[13] Y.A. Adebisi, A.J. Alaran, O.A. Bolanwina, W. Akande-Sholabi, D.E. Lucero-Princo, When it is available, will we take it? Social media users’ perception of hypothetical COVID-19 vaccine in Nigeria, Pan Afr Med J 38 (2021 Mar 2) 230, https://doi.org/10.11604/pamj.2021.38.230.27325.
[14] J. Aishana, Fact-check: does COVID-19 vaccine cause infertility in men, women? Int. Cent. Invest. Rep. (2021). Available at: https://www.icirg.org/act-check-does-covid-19-vaccine-cause-infertility-in-men-women/. (Accessed 5 July 2022).
[15] R. Schönbauer, Cameroonian refugees help bust COVID-19 myths in Nigeria, UNHCR Africa (2022). Available at: https://www.unhcr.org/news/stories/2022/6/604917564/cameroonian-refugees-help-bust-covid-19-myths-nigeria.html. (Accessed 5 July 2022).
